Fleet Bioprocessing Ltd. launch new service – Contract Development of Lateral Flow Devices!

We are excited to announce that Fleet Bioprocessing Ltd. are launching a new service: from today we will be offering contract development of lateral flow devices (LFDs) to our customers.

LFDs form a cornerstone of modern diagnostics, providing a rapid means to detect diseases in a point-of-care (POC) format that can be used in people’s own homes or in primary care, with broader applications spanning clinical, veterinary, industrial, and environmental settings. Traditionally LFDs were typically qualitative (yes/no) tests with limited sensitivity, but recent technological advances have increasingly allowed their application for sensitive, quantitative assays which can match the performance of lab based immunoassays such as ELISAs. In parallel with these technical advances, published market research consistently indicates strong future growth for lateral flow and other POC diagnostic technologies, driven by increasing demand for decentralised testing, home based diagnostics, and rapid clinical decision making.

New applications of LFDs are arising all the time, and Fleet will now be applying their world renowned immunoassay development skills to this field, from initial feasibility and optimisation through verification and validation studies under the exacting standards of ISO13485 and transfer to a long term manufacturer.

As part of this initiative we are very proud to be partnering with Lateral Dx Ltd. – leveraging our joint skills, we can combine Lateral Dx’s renowned prowess in LFD design and optimisation with Fleet’s world class assay verification and validation expertise to enable end-to-end development of devices for the most demanding regulated clinical applications.

Alastair Dent FRSC, Managing Director of Fleet Bioprocessing Ltd., said:

“Moving into the lateral flow space is a logical extension of Fleet’s existing strengths in immunoassay development. Although the end product of an LFD development may look very different to a clinical lab ELISA, many underlying assay development principles are shared, and Fleet’s strong focus on process reproducibility is just as important in this field. We have worked with Richard Campbell and his colleagues at Lateral Dx for over twenty years. There is a huge amount of mutual respect between the companies and we are delighted that they have agreed to partner with us in this new initiative.”

 Richard Campbell, Managing Director of Lateral Dx said:

“We are thrilled to formalise our long-standing collaboration with Fleet Bioprocessing through this new collaboration. At Lateral Dx, we have always believed that the most impactful diagnostic solutions arise when scientific expertise is combined with a rigorous, quality‑driven approach to development. Fleet’s reputation in immunoassay verification and validation is second to none, and together we can offer customers a truly end‑to‑end development pathway for next‑generation lateral flow devices. The demand for accurate, rapid, decentralised testing continues to grow, and this partnership positions us perfectly to help innovators bring high‑performance LFDs to market with confidence”

 You can find out more about Fleet’s new LFD services here and we would be delighted to talk to you about your needs in this area. Please contact us for a quick response!

Get in Touch